Stockreport

Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights

Pyxis Oncology, Inc.  (PYXS) 
PDF Non-dilutive funding to support development of first-in-concept lead Antibody-Drug Conjugate (ADC) asset, PYX-201 Pyxis Oncology retains rights to three other antibodie [Read more]